1. Home
  2. WINT vs ATCH Comparison

WINT vs ATCH Comparison

Compare WINT & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • ATCH
  • Stock Information
  • Founded
  • WINT 1992
  • ATCH 2022
  • Country
  • WINT United States
  • ATCH United States
  • Employees
  • WINT N/A
  • ATCH N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • ATCH
  • Sector
  • WINT Health Care
  • ATCH
  • Exchange
  • WINT Nasdaq
  • ATCH Nasdaq
  • Market Cap
  • WINT 2.2M
  • ATCH 2.5M
  • IPO Year
  • WINT 1995
  • ATCH N/A
  • Fundamental
  • Price
  • WINT $0.14
  • ATCH $0.19
  • Analyst Decision
  • WINT Hold
  • ATCH
  • Analyst Count
  • WINT 1
  • ATCH 0
  • Target Price
  • WINT $350.00
  • ATCH N/A
  • AVG Volume (30 Days)
  • WINT 5.2M
  • ATCH 33.6M
  • Earning Date
  • WINT 08-26-2025
  • ATCH 09-02-2025
  • Dividend Yield
  • WINT N/A
  • ATCH N/A
  • EPS Growth
  • WINT N/A
  • ATCH N/A
  • EPS
  • WINT N/A
  • ATCH N/A
  • Revenue
  • WINT N/A
  • ATCH $14,825,966.00
  • Revenue This Year
  • WINT N/A
  • ATCH N/A
  • Revenue Next Year
  • WINT N/A
  • ATCH N/A
  • P/E Ratio
  • WINT N/A
  • ATCH N/A
  • Revenue Growth
  • WINT N/A
  • ATCH 1066.77
  • 52 Week Low
  • WINT $0.10
  • ATCH $0.14
  • 52 Week High
  • WINT $662.00
  • ATCH $26.94
  • Technical
  • Relative Strength Index (RSI)
  • WINT 24.01
  • ATCH 49.97
  • Support Level
  • WINT $0.45
  • ATCH $0.17
  • Resistance Level
  • WINT $0.51
  • ATCH $0.25
  • Average True Range (ATR)
  • WINT 0.08
  • ATCH 0.03
  • MACD
  • WINT -0.05
  • ATCH 0.00
  • Stochastic Oscillator
  • WINT 8.93
  • ATCH 39.28

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About ATCH AtlasClear Holdings Inc. Common Stock

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

Share on Social Networks: